Lipoprotein(a) for risk assessment in patients with established coronary artery disease

Journal of the American College of Cardiology

Volumn 63, Issue 6, 2014, Pages 520-527

  O'Donoghue, Michelle L ^a   Morrow, David A ^a   Tsimikas, Sotirios ^b   Sloan, Sarah ^a   Ren, Angela F ^a   Hoffman, Elaine B ^a   Desai, Nihar R ^c   Solomon, Scott D ^a   Domanski, Michael ^d   Arai, Kiyohito ^b,e   Chiuve, Stephanie E ^a   Cannon, Christopher P ^a   Sacks, Frank M ^a   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

biomarkers; lipoprotein(a); risk stratification; secondary prevention

Indexed keywords

BIOMARKERS; LIPOPROTEIN(A); RISK STRATIFICATION; SECONDARY PREVENTION;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEIN(A); PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SECONDARY PREVENTION;

EID: 84893861519     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.09.042     Document Type: Article

References (46)

1. D.A. Tregouet, I.R. Konig, and J. Erdmann et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease Nat Genet 41 2009 283 285
2. P.R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard Genetically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
3. R. Clarke, J.F. Peden, and J.C. Hopewell et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease N Engl J Med 361 2009 2518 2528
4. G. Thanassoulis, C.Y. Campbell, and D.S. Owens et al. Genetic associations with valvular calcification and aortic stenosis N Engl J Med 368 2013 503 512
5. S. Erqou, S. Kaptoge, and P.L. Perry et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality JAMA 302 2009 412 423
6. N.J. Wald, M. Law, and H.C. Watt et al. Apolipoproteins and ischaemic heart disease: implications for screening Lancet 343 1994 75 79 (Pubitemid 24019347)
7. J. Suk Danik, N. Rifai, J.E. Buring, and P.M. Ridker Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women JAMA 296 2006 1363 1370 (Pubitemid 44427422)
8. P.R. Kamstrup, M. Benn, A. Tybjaerg-Hansen, and B.G. Nordestgaard Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study Circulation 117 2008 176 184
9. N. Rifai, J. Ma, and F.M. Sacks et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: the Physicians' Health Study Clin Chem 50 2004 1364 1371 (Pubitemid 38970643)
10. B.G. Nordestgaard, M.J. Chapman, and K. Ray et al. Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
11. M.H. Davidson, C.M. Ballantyne, and T.A. Jacobson et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists J Clin Lipidol 5 2011 338 367
12. C.P. Cannon, S. Shah, and H.M. Dansky et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
13. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
14. B. Kolski, and S. Tsimikas Emerging therapeutic agents to lower lipoprotein (a) levels Curr Opin Lipid 23 2012 560 568
15. N.R. Desai, P. Kohli, and R.P. Giugliano et al. AMG 145, a monoclonal antibody against pcsk9, significantly reduces lipoprotein (a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LAPLACE-TIMI 57 trial Circulation 128 2013 962 969
16. E. Braunwald, M.J. Domanski, and S.E. Fowler et al. Angiotensin- converting-enzyme inhibition in stable coronary artery disease N Engl J Med 351 2004 2058 2068
17. F.M. Sacks, M.A. Pfeffer, and L.A. Moye et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009 (Pubitemid 26338729)
18. C.P. Cannon, E. Braunwald, and C.H. McCabe et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504 (Pubitemid 38477774)
19. V.M. Maher, B.G. Brown, S.M. Marcovina, L.A. Hillger, X.Q. Zhao, and J.J. Albers Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a) JAMA 274 1995 1771 1774
20. J.S. Skinner, M. Farrer, C.J. Albers, K. Piper, H.A. Neil, and P.C. Adams Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery Heart 78 1997 131 135 (Pubitemid 27404946)
21. K. Berg, G. Dahlen, B. Christophersen, T. Cook, J. Kjekshus, and T. Pedersen Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study Clin Genet 52 1997 254 261 (Pubitemid 28068613)
22. P. Stubbs, M. Seed, D. Lane, P. Collinson, F. Kendall, and M. Noble Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes Eur Heart J 19 1998 1355 1364 (Pubitemid 28427137)
23. M.G. Shlipak, J.A. Simon, and E. Vittinghoff et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause JAMA 283 2000 1845 1852 (Pubitemid 30207621)
24. M.N. Zairis, J.A. Ambrose, and S.J. Manousakis et al. The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting: the Global Evaluation of New Events and Restenosis After Stent Implantation Study J Am Coll Cardiol 40 2002 1375 1382 (Pubitemid 35192859)
25. C.H. Saely, L. Koch, and F. Schmid et al. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients Eur J Clin Invest 36 2006 91 97
26. J.J. Albers, A. Slee, and K.D. O'Brien et al. Relationship of apolipoproteins A-1 and B, and lipoprotein (a) to cardiovascular outcomes in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes) J Am Coll Cardiol 62 2013 1575 1579
27. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188 (Pubitemid 17189972)
28. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558 (Pubitemid 34746062)
29. S.M. Grundy, J.I. Cleeman, and C.N. Merz et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
30. W.Y. Craig, L.M. Neveux, G.E. Palomaki, M.M. Cleveland, and J.E. Haddow Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies Clin Chem 44 1998 2301 2306 (Pubitemid 28511752)
31. J. Danesh, R. Collins, and R. Peto Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies Circulation 102 2000 1082 1085
32. A. Bennet, E. Di Angelantonio, and S. Erqou et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data Arch Intern Med 168 2008 598 608 (Pubitemid 351468395)
33. S. Kiechl, J. Willeit, and M. Mayr et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study Arterioscler Thromb Vasc Biol 27 2007 1788 1795 (Pubitemid 47207175)
34. S. Tsimikas, Z. Mallat, and P.J. Talmud et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events J Am Coll Cardiol 56 2010 946 955
35. G. Luc, J.M. Bard, and D. Arveiler et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME study Atherosclerosis 163 2002 377 384 (Pubitemid 34615830)
36. P.R. Kamstrup, A. Tybjaerg-Hansen, and B.G. Nordestgaard Extreme lipoprotein(a) levels and improved cardiovascular risk prediction J Am Coll Cardiol 61 2013 1146 1156
37. T. Linden, W. Taddei-Peters, and L. Wilhelmsen et al. Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery Atherosclerosis 137 1998 175 186 (Pubitemid 28175390)
38. V.W. Armstrong, P. Cremer, and E. Eberle et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels Atherosclerosis 62 1986 249 257 (Pubitemid 17208644)
39. C. Marburger, R. Hambrecht, and J. Niebauer et al. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men Am J Cardiol 73 1994 742 746 (Pubitemid 24128882)
40. G.R. Thompson, V.M. Maher, and S. Matthews et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis Lancet 345 1995 811 816
41. W.E. Boden, J.L. Probstfield, and T. Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
42. Armitage J, on Behalf of the THRIVE Collaborative Group. HPS2-THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events. Paper presented at: American College of Cardiology Scientific Sessions; March 9 to 11, 2013; San Francisco, CA.
43. B. Ky, A. Burke, and S. Tsimikas et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans J Am Coll Cardiol 51 2008 1653 1662 (Pubitemid 351626406)
44. F. Dati, J.R. Tate, S.M. Marcovina, and A. Steinmetz First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay-Lp(a) SRM 2B Clin Chem Lab Med 42 2004 670 676 (Pubitemid 38979146)
45. S. Tsimikas, J. Witztum, and A. Catapano Effect of mipomersen on lipoprotein(a) in patients with hypercholesterolemia across four phase III studies J Am Coll Cardiol 59 2012 E1494 [abstr]
46. E. Merki, M. Graham, and A. Taleb et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice J Am Coll Cardiol 57 2011 1611 1621